263 related articles for article (PubMed ID: 28922685)
1. Neoadjuvant systemic therapy for breast cancer: the Westmead experience.
Cocco AM; Messer D; Brown A; Sriram N; Gilchrist J; Al-Mansouri L; Kefford R; Meybodi F; French J; Hsu J; Elder E
ANZ J Surg; 2018 Jun; 88(6):640-644. PubMed ID: 28922685
[TBL] [Abstract][Full Text] [Related]
2. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.
Armer JM; Ballman KV; McCall L; Ostby PL; Zagar E; Kuerer HM; Hunt KK; Boughey JC
JAMA Surg; 2019 Sep; 154(9):800-809. PubMed ID: 31314062
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
[TBL] [Abstract][Full Text] [Related]
5. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
6. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
7. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
[TBL] [Abstract][Full Text] [Related]
8. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
9. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
10. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
[TBL] [Abstract][Full Text] [Related]
11. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
13. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
[TBL] [Abstract][Full Text] [Related]
14. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: Work in progress.
Rubio IT
Eur J Surg Oncol; 2016 Mar; 42(3):326-32. PubMed ID: 26774943
[TBL] [Abstract][Full Text] [Related]
16. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
19. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
Oven Ustaalioglu BB; Bilici A; Kefeli U; Seker M; Yildirim E; Salepci T; Oncel M; Kement M; Gumus M
Oncology; 2010; 79(1-2):105-11. PubMed ID: 21088436
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
